|Articles|June 12, 2023
Recapping The First Two Days Of ASHP Summer Meetings 2023
What stood out on Sunday and Monday at the 2023 ASHP Summer Meetings in Baltimore?
Advertisement
Novel ADHD Therapy More Tolerable, Less Effective Than Current Treatment Options
Centanafadine is a serotonin-norepinephrine-dopamine triple reuptake inhibitor.
CGRP Inhibitors Significantly Reduce Disability in Migraine
Study results add to the body of evidence demonstrating the efficacy of CGRP inhibitors for migraine treatment and prophylaxis.
Why Are Pharmacogenomics Not Fully Implemented in Health Care?
A look at how the genetics-based research field can become more fully integrated in all areas of health care going forward.
Optimizing Oncology Drug Interaction Alerts to Improve Patient Safety
Although excessive use can lead to fatigue, alerts can help proactively identify and prevent drug interactions.
ASHP: Adalimumab Biosimilar Pipeline Review
At least 6 adalimumab biosimilars are set to launch in July 2023.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Embedded Pharmacists Are Vital Yet Underutilized in Diabetes Care
2
The Prodigious PBM Pivot: How Supply Chain Entities Will Move Forward After CAA 2026
3
Executive Order Calls for Realignment of Childhood Vaccines
4
Polypharmacy for Older Adults With Diabetes Reaches as High As 95.3%
5